108 related articles for article (PubMed ID: 35731106)
41. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.
Benlloch S; Galbis-Caravajal JM; Martín C; Sanchez-Paya J; Rodríguez-Paniagua JM; Romero S; Mafe JJ; Massutí B
Cancer; 2006 Oct; 107(8):1859-65. PubMed ID: 16983705
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.
Liu N; Sun RZ; Du J; Dong QZ; Fan CF; Li QC; Wang EH; Liu Y
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):e44-e51. PubMed ID: 28800007
[TBL] [Abstract][Full Text] [Related]
43. Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2010; 54(3):277-82. PubMed ID: 20518411
[TBL] [Abstract][Full Text] [Related]
44. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
45. Liquid biopsy approaches for pleural effusion in lung cancer patients.
Baburaj G; Damerla RR; Udupa KS; Parida P; Munisamy M; Kolesar J; Rao M
Mol Biol Rep; 2020 Oct; 47(10):8179-8187. PubMed ID: 33029702
[TBL] [Abstract][Full Text] [Related]
46. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer.
Xu CH; Cao L; Zhang XW; Yan J; Yu LK
Tumour Biol; 2015 Jun; 36(6):4397-403. PubMed ID: 25636447
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
49. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
51. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
[TBL] [Abstract][Full Text] [Related]
52. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
53. Label-Free Quantitative Proteomics Identifies Novel Biomarkers for Distinguishing Tuberculosis Pleural Effusion from Malignant Pleural Effusion.
Pan L; Zhang X; Jia H; Huang M; Liu F; Wang J; Du B; Wei R; Sun Q; Xing A; Li Q; Zhang Z
Proteomics Clin Appl; 2020 Jan; 14(1):e1900001. PubMed ID: 31715074
[TBL] [Abstract][Full Text] [Related]
54. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
Javadi J; Dobra K; Hjerpe A
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
[TBL] [Abstract][Full Text] [Related]
55. [Thoracocentesis for the assessment of lung cancer with pleural effusion].
Martín Díaz E; Arnau Obrer A; Martorell Cebollada M; Cantó Armengod A
Arch Bronconeumol; 2002 Oct; 38(10):479-84. PubMed ID: 12372198
[TBL] [Abstract][Full Text] [Related]
56. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
57. A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.
Yan J; Wei Q; Jian W; Liu J; Tang H; Ge J; Zhou J; Zhao T
Int J Clin Exp Pathol; 2014; 7(9):5810-8. PubMed ID: 25337222
[TBL] [Abstract][Full Text] [Related]
58. Thyroid transcription factor-1 immunocytochemical staining of pleural fluid cytocentrifuge preparations for detection of small cell lung carcinoma.
Liu J; Farhood A
Acta Cytol; 2004; 48(5):635-40. PubMed ID: 15471255
[TBL] [Abstract][Full Text] [Related]
59. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
Song Z; Wang W; Li M; Liu J; Zhang Y
Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
[TBL] [Abstract][Full Text] [Related]
60. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study.
Chhieng DC; Ko EC; Yee HT; Shultz JJ; Dorvault CC; Eltoum IA
Diagn Cytopathol; 2001 Dec; 25(6):356-60. PubMed ID: 11747231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
